ArticleInternational journal of general medicine2025
Relationship Between Glycosylated Hemoglobin Concentration and Prognosis of Acute ST-Segment Elevation Myocardial Infarction in Non-Diabetic Patients.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the relationship between glycosylated hemoglobin (HbA1c) concentration at admission and the prognosis of acute ST-segment elevation myocardial infarction (STEMI) in non-diabetic patients. Methods: A total of 142 non-diabetic patients with acute STEMI who underwent emergency percutaneous coronary intervention (PCI) in our hospital between January 2023 and December 2024 were enrolled in this study. HbA1c levels and baseline data for all patients were obtained at admission. According to the HbA1c level, patients were divided into a normal blood glucose level group (group A, HbA1c & lt; 5.7%, N = 57) and a pre-diabetic group (group B, 5.7% ≤ HbA1c ≤ 6.4%, N = 85). The occurrence of major cardiovascular events (MACE) was compared between the two groups after PCI during one-year follow-up. Results: The levels of serum FPG, BNP and the number of patients with multivessel diseases in group B were higher than those in group A (all p < 0.05). The LVEF in group B was significantly lower than in Group A (P = 0. 017). The total incidence of major cardiovascular events (MACE) within 1 year after PCI was significantly higher in group B than in group A (P = 0. 047). In addition, the risk of MACE in group B was 4.98 times higher than that in group A. Conclusion: HbA1c can be used as an independent predictor of MACE in non-diabetic STEMI patients. The control of blood glucose levels in pre-diabetic patients with STEMI should be given high emphasis to improve prognosis after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.